George Tidmarsh, who helmed the FDA’s Center for Drug Evaluation and Research, resigned Sunday following a complaint by biopharma investor Kevin Tang, whose affiliated company, Aurinia Pharmaceuticals, filed a lawsuit against the former regulator on Sunday.
